Mirati Therapeutics Presents Positive Clinical Data with Investigational Adagrasib as Monotherapy and in Combination with Cetuximab in Patients with KRAS G12C-Mutated Colorectal Cancer ...Middle East

SAN DIEGO, Sept. 19, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced results from a cohort of the Phase 1/2 KRYSTAL–1 study evaluating adagrasib at the 600mg BID dose as both monotherapy and in combination with...

Hence then, the article about mirati therapeutics presents positive clinical data with investigational adagrasib as monotherapy and in combination with cetuximab in patients with kras g12c mutated colorectal cancer was published today ( Sunday 19/09/2021 - 05:45 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Mirati Therapeutics Presents Positive Clinical Data with Investigational Adagrasib as Monotherapy and in Combination with Cetuximab in Patients with KRAS G12C-Mutated Colorectal Cancer )

Also on site :

• Citizens Bank Customers Targeted in Third-Party Data Breach .. PYMNTS.com
• Caesars faces new lawsuit after second alleged data security breach claims
• BBC warns programmes will be cut unless TV goes online-only